Pharmaceuticals, Biotechnology and Life Sciences
Vivoryon Therapeutics a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and Simcere Pharmaceutical Group have announced that…
Oligomerix, Inc., a privately held company focused on therapeutics targeting tau for Alzheimer’s disease similar dementias, which is also currently seeking strategic partners to support the acceleration and advancement of those programs, has appointed Robert Foerster as Chief Financial Officer.
Actinogen Medical’s trial showed cognitive improvement in healthy elderly subjects dosed with 20mg Xanamem daily, with statistically significant reduction in serum cortisol following treatment with Xanamem.
Tetra Therapeutics has surpassed 50% enrollment – 65% of which are Hispanic patients– in its Phase 2 clinical trial (PICASSO…
Biohaven Pharmaceutical started a Phase 2/3 clinical trial of trigriluzole (BHV-4157), a novel glutamate modulator, in patients with mild-to-moderate Alzheimer’s disease (AD).
AgeneBio has enrolled its first out of 830 patient in a Phase 3 clinical trial of its investigational medication AGB101, to treat amnestic Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD).
Amneal Pharmaceuticals will shortly start selling its prescription medicine used to treat memory problems associated with Alzheimer’s disease.Rivastigmine Transdermal System, generic version of Novartis’ Exelon Patch, after getting the FDA’s approval.
Probiodrug, a Germany-based biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD) and other neurodegenerative disorders, has reported that Last Patient’s Last Visit (LPLV) occurred on 05 April 2017 in the currently running Phase 2a SAPHIR study investigating the QC-inhibitor PQ912 in patients with early AD.